Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Energy Fuels Aktie: Achtung, Aufholpotenzial! (Aktiencheck) +++ ENERGY FUELS Aktie -3,11%

DIANTHUS Aktie

 >DIANTHUS Aktienkurs 
15.85 EUR    (Tradegate)
Ask: 15.9 EUR / 374 Stück
Bid: 15.8 EUR / 379 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
DIANTHUS Aktie über LYNX handeln
>DIANTHUS Performance
1 Woche: +5,3%
1 Monat: +1,0%
3 Monate: +7,8%
6 Monate: -34,0%
1 Jahr: -35,0%
laufendes Jahr: -27,6%
>DIANTHUS Aktie
Name:  DIANTHUS THERAPEUTICS
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US2528281080 / A3ERZ4
Symbol/ Ticker:  87E (Frankfurt) / DNTH (NASDAQ)
Kürzel:  FRA:87E, ETR:87E, 87E:GR, NASDAQ:DNTH
Index:  -
Webseite:  https://dianthustx.com/
Marktkapitalisierung:  507.67 Mio. EUR
Umsatz:  5.65 Mio. EUR
EBITDA:  -101.51 Mio. EUR
Gewinn je Aktie:  -2.115 EUR
Schulden:  1.21 Mio. EUR
Liquide Mittel:  228.18 Mio. EUR
Umsatz-/ Gewinnwachstum:  33.1% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  103.24 / 1.84 / -
Gewinnm./ Eigenkapitalr.:  - / -28.73%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  DIANTHUS
Letzte Datenerhebung:  05.07.25
>DIANTHUS Eigentümer
Aktien: 32.16 Mio. St.
f.h. Aktien: 10.99 Mio. St.
Insider Eigner: 7.87%
Instit. Eigner: 119.96%
>DIANTHUS Peer Group

 
29.05.25 - 13:03
 Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire EN)
 
NEW YORK and WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the Company's participation in the Jefferies Global Healthcare Conference. Marino Garcia, Chief Executive Officer, will participate in a fireside chat on Thursday, June 5, 2025 at 9:55 a.m. EDT in New York City and will host one-on-one meetings with investors....
22.05.25 - 22:12
 Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors (GlobeNewswire EN)
 
Dr. Read brings >30 years of leadership and scientific expertise in the biopharmaceutical industry...
12.05.25 - 22:03
 Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire EN)
 
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG)...
29.04.25 - 13:03
 Dianthus Therapeutics to Participate in Two Upcoming Investor Events (GlobeNewswire EN)
 
NEW YORK and WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at two upcoming investor events....
03.04.25 - 17:30
 Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
 
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road....
12.03.25 - 00:00
 Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
 
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of 4.71% and 5.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?...
11.03.25 - 23:12
 Dianthus Therapeutics GAAP EPS of -$0.81 beats by $0.04, revenue of $1.33M beats by $0.47M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
11.03.25 - 21:03
 Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results (GlobeNewswire EN)
 
Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25...
05.03.25 - 13:03
 Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors (GlobeNewswire EN)
 
Mr. King launched the first approved biologic and C5 complement inhibitor into the Myasthenia Gravis market and helped set the foundation for the multi-billion dollar C5 franchise of Alexion...
26.02.25 - 13:03
 Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire EN)
 
NEW YORK and WALTHAM, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the following investor conferences:...
30.01.25 - 13:03
 Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences (GlobeNewswire EN)
 
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February:...
08.01.25 - 13:03
 Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
 
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco....
08.11.24 - 06:36
 Dianthus Therapeutics GAAP EPS of -$0.74, revenue of $2.17M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
08.11.24 - 00:48
 Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
 
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -25.42% and 102.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?...
04.11.24 - 13:03
 Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences (GlobeNewswire EN)
 
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024:...
15.10.24 - 13:03
 Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting (GlobeNewswire EN)
 
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18, 2024 in Savannah, Georgia....
09.10.24 - 11:15
 Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength? (Zacks)
 
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road....
03.10.24 - 17:15
 Dianthus started at outperform by Oppenheimer on DNTH103 opportunity (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Kein Kaiser kann, was unser ist, verschenken. - Friedrich Johann Christoph Schiller
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!